Xarelto — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson Xarelto — Sales to customers (Note 9) increased by 2.3% to $1.27B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 7.3%, from $1.18B to $1.27B. Over 2 years (FY 2021 to FY 2024), Xarelto — Sales to customers (Note 9) shows relatively stable performance with a 0.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market adoption or successful commercial execution, while a decrease may signal patent expiration, increased competition, or declining therapeutic relevance.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific pharmaceutical product line to extern...
Peer comparison
Comparable to specific drug or product line revenue disclosures found in the segment reporting of other major pharmaceutical companies.
jnj_segment_xarelto_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.18B | $1.14B | $1.27B | $1.33B | $1.02B | $1.22B | $1.38B | $1.16B | $1.25B | $1.04B | $1.17B | $1.18B | $1.35B | $1.38B | $1.24B | $1.27B |
| QoQ Change | — | -3.4% | +11.8% | +4.9% | -23.8% | +19.9% | +13.1% | -16.1% | +8.1% | -17.1% | +13.3% | +0.9% | +14.2% | +2.1% | -10.0% | +2.3% |
| YoY Change | — | — | — | — | -13.8% | +7.0% | +8.3% | +13.8% | +2.6% | — | +1.6% | -5.3% | — | +33.2% | +5.8% | +7.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's xarelto — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported xarelto — sales to customers (note 9) of $1.27B in Q3 2025.
- How has Johnson & Johnson's xarelto — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's xarelto — sales to customers (note 9) increased by 7.3% year-over-year, from $1.18B to $1.27B.
- What is the long-term trend for Johnson & Johnson's xarelto — sales to customers (note 9)?
- Over 2 years (2021 to 2024), Johnson & Johnson's xarelto — sales to customers (note 9) has grown at a 0.6% compound annual growth rate (CAGR), from $4.69B to $4.75B.
- What does xarelto — sales to customers (note 9) mean?
- The total revenue earned from selling a specific pharmaceutical product to customers.